Dataset Information

Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma.

ABSTRACT:

Background

Improvement in lung function after macrolide antibiotic therapy has been attributed to reduction in bronchial infection by specific bacteria. However, the airway might be populated by a more diverse microbiota, and clinical features of asthma might be associated with characteristics of the airway microbiota present.

Objective

We sought to determine whether relationships exist between the composition of the airway bacterial microbiota and clinical features of asthma using culture-independent tools capable of detecting the presence and relative abundance of most known bacteria.

Methods

In this pilot study bronchial epithelial brushings were collected from 65 adults with suboptimally controlled asthma participating in a multicenter study of the effects of clarithromycin on asthma control and 10 healthy control subjects. A combination of high-density 16S ribosomal RNA microarray and parallel clone library-sequencing analysis was used to profile the microbiota and examine relationships with clinical measurements.

Results

Compared with control subjects, 16S ribosomal RNA amplicon concentrations (a proxy for bacterial burden) and bacterial diversity were significantly higher among asthmatic patients. In multivariate analyses airway microbiota composition and diversity were significantly correlated with bronchial hyperresponsiveness. Specifically, the relative abundance of particular phylotypes, including members of the Comamonadaceae, Sphingomonadaceae, Oxalobacteraceae, and other bacterial families were highly correlated with the degree of bronchial hyperresponsiveness.

Conclusion

The composition of bronchial airway microbiota is associated with the degree of bronchial hyperresponsiveness among patients with suboptimally controlled asthma. These findings support the need for further functional studies to examine the potential contribution of members of the airway microbiota in asthma pathogenesis.

SUBMITTER: Huang YJ

PROVIDER: S-EPMC3037020 | biostudies-literature | 2011 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma.

Huang Yvonne J YJ Nelson Craig E CE Brodie Eoin L EL Desantis Todd Z TZ Baek Marshall S MS Liu Jane J Woyke Tanja T Allgaier Martin M Bristow Jim J Wiener-Kronish Jeanine P JP Sutherland E Rand ER King Tonya S TS Icitovic Nikolina N Martin Richard J RJ Calhoun William J WJ Castro Mario M Denlinger Loren C LC Dimango Emily E Kraft Monica M Peters Stephen P SP Wasserman Stephen I SI Wechsler Michael E ME Boushey Homer A HA Lynch Susan V SV

The Journal of allergy and clinical immunology 20101230 2

<h4>Background</h4>Improvement in lung function after macrolide antibiotic therapy has been attributed to reduction in bronchial infection by specific bacteria. However, the airway might be populated by a more diverse microbiota, and clinical features of asthma might be associated with characteristics of the airway microbiota present.<h4>Objective</h4>We sought to determine whether relationships exist between the composition of the airway bacterial microbiota and clinical features of asthma usin ...[more]

PMID: 21194740

Similar Datasets

Project description:ObjectiveControl of airway inflammation is the cornerstone of asthma management. The aim of the present pilot study was to assess the effects of a leukotriene receptor antagonist (LTRA) added to a basic treatment of inhaled corticosteroids (ICS) and long-acting beta-agonist (LABA) on airway hyperresponsiveness, inflammation, and quality of life in well-controlled patients with asthma.Research design and methodsSeventeen patients (age 18-65, 11 women) with well-controlled asthma presenting airway hyperresponsiveness to mannitol and methacholine challenge were given add-on montelukast on a stable ICS + LABA for 4 weeks. Quality of life and selected parameters of airway inflammation were measured at baseline and at study end. (ClinicalTrials.gov (NCT01725360)).ResultsAdding montelukast to ICS + LABA resulted in an increase in mean FEV1 (+4.5%, p = 0.057), cumulated higher dose of mannitol (+32.5%, p = 0.023) and methacholine (+17.2%, 0.237) in the provocation test, lower airway reactivity with mannitol and methacholine (response dose ratio (RDR) -50.0%, p = 0.024 and -44.3%, p = 0.006, respectively), and improved airway sensitivity to mannitol and methacholine (+12.1%, p = 0.590 and +48.0%, p = 0.129 for PD15 and PD20 FEV1, respectively). Changes in inflammation parameters (blood eosinophil count, serum eosinophil cationic protein, and exhaled nitric oxide) were consistent with these findings. Asthma-related quality of life improved significantly in all domains and overall (from 5.3 at baseline to 6.1 at the final visit, p < 0.001). The main limitation was the absence of a control group.ConclusionThe consistency of the changes in airway hyperresponsiveness and inflammation as well as in quality of life observed with an add-on therapy with montelukast in well-controlled asthma patients during 4 weeks suggests that residual inflammation may represent an area for further improvement of asthma control to be explored in adequately powered randomized controlled trials.

Dataset Information

Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma.

Background

Objective

Methods

Results

Conclusion

Publications

Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets